- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02543788
CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS
CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS: DEMYELINATING AND/OR PRIMARY DEGENERATIVE PATHOPHYSIOLOGY?
Patients with multiple sclerosis (MS) may show chronic signs of optic neuropathy (CON) that may follow acute optic neuritis (secondary form of CON, S-CON) or occur independently of any acute demyelinating lesion of the optic nerve (primary form of CON, P-CON). In both S-CON and P-CON, a long term progressive ganglion cell axonal loss occurs. This axonal damage could be secondary to retrograde atrophy of axons within plaques of demyelination or a primary progressive degeneration of ganglion cells, but the underlying physiopathology has not been fully questioned in the different profile types of CON.
In this project, investigators aim at understanding the pathophysiology of S-CON and P-CON, i.e. secondary to demyelination or primary degeneration, in patients complaining of persistent visual complaints. In a first cross sectional study, 30 MS patients with mild to moderate P-CPON or S-CON and 30 age-matched control subjects will perform an extensive neuro-ophthalmological assessment including clinical examination, visual evoked potentials (pattern and low contrast), electroretinogram (pattern and multifocal ERG), OCT (peripapillary and macular volume scan segmentation protocols) and MRI of the optic nerve. In these patients with mild to moderate CON, investigators aim at differentiating patients showing predominant demyelination from those showing pure or predominant axonal degeneration. Visual function assessment and degree of axonal degeneration will be compared and correlated in the two types of underlying pathophysiology and in the group of control subject. In a following longitudinal study, the patients will be re-assessed a year later in order to evaluate the progression of CON in both profile types. Our hypothesis would be that visual function and progression is worse in the degeneration group as compared to the demyelination group. This study should help to find reliable measures of the pathophysiology of CON and correlate it with the long-term visual prognostic of the disease.
Study Overview
Status
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bron
-
France, Bron, France, 69677
- Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion criteria for patients
- All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria (2010).
- All patients may present a chronic visual complaint.
- All patients may present mild to moderate chronic optic neuropathy (cf infra)
- All patients may not have recent acute optic neuritis (<2 years)
- All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.
- Age: > 18
- Able to understand the instructions
- Having a health coverage
- Able to sit down for 1 hour Diagnosis of mild to moderate chronic optic neuropathy
For the diagnosis of optic neuropathy, patients will have to meet 3 of the 6 next criteria:
- Far Visual Acuity (ETDRS charts, 100% contrast) < 85 letters
- Far Visual Acuity (ETDRS charts, 2.5% contrast) < 60 letters
- Mean visual field defect on static perimetry> 2dB
- Mean pRNFL in OCT < 80 µ.
- Color vision score > 35
Disc pallor Diagnosis of mild to moderate optic neuropathy
- Far Visual Acuity (ETDRS charts, 100% contrast) >70 letters Diagnosis of chronic optic neuropathy
Stable or worsening of visual acuity, visual field and/or RNFL in OCT, at 6 month of interval
- Inclusion criteria for controls
- Age > 18 years
- Visual acuity score (ETDRS) > 85
- Able to understand the instructions
- Having a health coverage
- Informed and consenting to give his written consent
Exclusion Criteria:
Non inclusion criteria for patients.
Ophthalmological
- Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…)
- Ocular instability in primary position of gaze
Neurological
- Ongoing seizure
- Severe handicap that does not allow sitting down position for 1 hour
General
- Unstable medical state
- Severe renal insufficiency
- Allergy to gadolinium
- Claustrophobia
- Implanted electrical stimulator (pace maker)
- Metallic prosthesis or orthesis, cochlear implants
- Intraocular foreign material
- Pregnancy (on questioning)
- Tutelage or any legal protection measure
Non inclusion criteria for controls
- Any ophthalmological disorder that could impair corrected visual acuity
- Any neurological disorder
- MRI contraindication
- Allergy to gadolinium
- Severe renal insufficiency
- Claustrophobia
- Implanted electrical stimulator (pace maker)
- Metallic prosthesis or orthesis, cochlear implants
- Intraocular foreign material
- Pregnancy (on questioning)
- Tutelage or any legal protection measure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: patients
patients with chronic optic neuropathy in multiple sclerosis
|
|
Other: Controls
healthy volunteers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Day0 15' P100 VEP latency at one year
Time Frame: D0 and one year
|
15' VEP latency may be the best outcome that allow differentiating patients from controls, and each of the sub-group of patients
|
D0 and one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Day0 100%, 2.5% and 1.25% ETDRS Visual Acuity at one year (composite measure)
Time Frame: D0 and one year
|
D0 and one year
|
Change from Day0 Visual field macular threshold and corrected mean visual field deficit at one year (composite measure)
Time Frame: D0 and one year
|
D0 and one year
|
change frome Day0 NEI-VFQ 25 composite score and 10-item score at one year (composite measure)
Time Frame: D0 and one year
|
D0 and one year
|
Change from Day0 N75, P100, N135 VEP latency and amplitude; P50, N95 ERG latency and amplitude; p1 mERG latency and amplitude at one year (composite measure)
Time Frame: D0 and one year
|
D0 and one year
|
Change from Day0 OCT peripapillary RNLF thickness and Ganglion cell layer average thickness on macular dense volume at one year (composite measure)
Time Frame: D0 and one year
|
D0 and one year
|
MRI presence or absence of optic nerve inflammatory signs on diameter of the optic nerve
Time Frame: D0
|
D0
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Caroline TILIKETE, MD, Unité de Neuro-Ophtalmologie - Hôpital Neurologique - HOSPICES CIVILS DE LYON - France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014.850
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Optic Neuropathy in Multiple Sclerosis
-
Wills EyeUnited States Department of DefenseCompletedTrauma | Multiple Sclerosis (MS) | Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)United States
-
Clene NanomedicineClene Australia Pty LtdTerminatedRelapsing Remitting Multiple Sclerosis | Optic Neuropathy | Optic; Neuritis, With DemyelinationUnited States, Canada, Australia
-
Institut National de la Santé Et de la Recherche...BiogenUnknownNervous System Diseases | Progressive Multiple Sclerosis | Multiple Sclerosis | Eye Diseases | Optic Neuritis | Optic Nerve Diseases | Relapsing Remitting Multiple SclerosisFrance
-
Shenzhen Beike Bio-Technology Co., Ltd.The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical... and other collaboratorsUnknownProgressive Multiple Sclerosis | Neuromyelitis Optica.China
-
Cedars-Sinai Medical CenterRecruitingMultiple Sclerosis | Clinically Isolated Syndrome | Multiple Sclerosis, Relapsing-Remitting | Healthy Aging | Neurologic Disorder | Neuromyelitis Optica Spectrum Disorders | Radiologically Isolated Syndrome | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive | Neurologic... and other conditionsUnited States
-
Neuromed IRCCSUniversity of Rome Tor VergataNot yet recruitingHealthy | Neuromyelitis Optica | Relapsing-Remitting Multiple Sclerosis (RRMS)Italy
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Medical University of ViennaRecruitingMultiple Sclerosis, Relapsing-Remitting | Optic NeuritisAustria
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States